Dajun Yang, Ascentage Pharma CEO

Com­mer­cial-stage blood can­cer biotech files for US dual list­ing

As­cen­t­age Phar­ma, a Hong Kong-list­ed blood can­cer biotech, is plan­ning a dual list­ing in the US as it pre­pares for ad­di­tion­al drug launch­es, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.